Anglo-Swedish drug maker AstraZeneca said Tuesday that Indian drug maker Ranbaxy Laboratories has applied to manufacture a copy of its top-selling anti-heartburn drug Nexium, challenging patents that are due to expire in 2018. AstraZeneca has 45 days to begin a patent infringement lawsuit against Ranbaxy.
October 19, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Anglo-Swedish drug maker AstraZeneca PLC said Tuesday that Indian drug maker Ranbaxy Laboratories Ltd. has applied to manufacture a copy of its top-selling drug Nexium, which is used for treating persistent heartburn caused by acid reflux disease.
AstraZeneca said Ranbaxy submitted an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the 20 milligram and 40 milligram versions of Nexium, challenging patents that are due to expire in 2018.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
A prominent AV-rated Education Law firm seeks an associate with 5+ years experience. The role will primarily involve advice and counsel in ...
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
